Sylvie Freeman

ORCID: 0000-0003-1869-180X

Colleges, School and Institutes

External positions

, Weatherall Institute of Molecular Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.

1 Oct 2017 → …
View graph of relations

Most downloaded publications

A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia
Robert Hills, Sylvie Freeman, 30 Sep 2016, In : Leukemia.

Research output: Contribution to journal › Article

115 downloads
Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage
& 13 others, , Sylvie Freeman, Charles Craddock, 25 Jul 2016, In : The Journal of Experimental Medicine. 213, 8, p. 1513-35 23 p.

Research output: Contribution to journal › Article

111 downloads
Assessment of Minimal Residual Disease in Standard-Risk AML
Robert Hills, Sylvie Freeman & 2 others, , 4 Feb 2016, In : The New England Journal of Medicine. 374, p. 422-433

Research output: Contribution to journal › Article

107 downloads
Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party
Sylvie Freeman & 4 others, , 12 Jan 2018, In : Blood.

Research output: Contribution to journal › Article

99 downloads
Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia
Naeem Khan, Robert Hills, Jerrald Rector & Sylvie Freeman, 26 Sep 2016, In : PLoS ONE. 11, 9, doi: 10.1371/journal.pone.0163291.

Research output: Contribution to journal › Article

60 downloads

Recent publications

MRD evaluation of AML in clinical practice: are we there yet?
Sylvie Freeman, 6 Dec 2019, In : Hematology. 2019, 1, p. 557-569

Research output: Contribution to journal › Article

Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia
Sylvie Freeman, 22 Oct 2019, In : Blood Advances. 3, 20, p. 3052-3061 10 p.

Research output: Contribution to journal › Article

Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML
Sylvie Freeman & 4 others, , 1 Apr 2019, In : The Journal of Experimental Medicine. 216, 4, p. 966-981 16 p.

Research output: Contribution to journal › Article

View all (41)